Pneuma Respiratory, the North Carolina based start-up that is focused on treatments for lung conditions, has developed the first fully digital, soft mist inhaler. The inhaler electronically detects a user's inhalation and automatically injects medication droplets into their lungs. This allows users to verify their dosage in real time via a mobile app. This technology has the potential to help the more than 40 million people who suffer from asthma or Chronic Obstructive Pulmonary Disease in the US overcome issues with medication dosage. Pneuma Respiratory’s technology, which is able to deliver different sized droplets of medicine to different areas of the lungs could help the company disrupt the biologics market. For background, biologics are drugs produced from living organisms or contain components of living organisms and have the ability to target specific molecules within the human body — the global biologics market is anticipated to reach $400 billion by 2025, up from $277 billion in 2015, according to a new report by Grand View Research.

Aaron White